Low-dose atovaquone for prophylaxis of Pneumocystis jirovecii pneumonia in patients with connective tissue diseases: an open-label, multicentre, single-arm, phase II trial

ABSTRACT: Objectives: Pneumocystis jirovecii pneumonia (PCP) is a life-threatening complication that occurs in immunocompromised individuals, including patients with connective tissue diseases under glucocorticoid treatments. Trimethoprim-sulfamethoxazole (TMP-SMX) and atovaquone 1500 mg/d, the fir...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Tomoaki Ida, Shunsuke Furuta, Yosuke Inaba, Taro Iwamoto, Shuhei Kameda, Yoshihisa Kobayashi, Kohei Takahashi, Tatsuro Takahashi, Tomohiro Tamachi, Masahiro Yasui, Hiroshi Nakajima
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Elsevier 2025-06-01
Serie:	EULAR Rheumatology Open
Accesso online:	http://www.sciencedirect.com/science/article/pii/S3050708125000308
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!